🏢 官网IRQDELCodex · 实盘不做把握 2/10
北京时间·🕒 发布 21:21:00时区推断·⟳ 抓取 21:25:39·⚡ 决策 07-23 21:27:10 +1m31s·95.9 天前
QuidelOrtho发布毒理检测主题播客，未披露订单、产品获批或业绩增量
这只是公司Science Bytes播客内容发布，讨论毒理检测趋势和ADLM指导意见，没有新增订单、监管获批、产品商业化或业绩指引。
📄 原文QDEL↗ 原文
Beyond Fentanyl: How the Drug Crisis Is Changing
07/23/2026 Download this Press Release PDF Format (opens in new window) SAN DIEGO , July 23, 2026 /PRNewswire/ -- Quide…
不做 QuidelOrtho（QDEL.US）
品牌/教育类播客发布，无明确方向、无金额量级、无产品获批或订单增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 low · price-in 风险 low ↗
关键理由
- 这只是公司Science Bytes播客内容发布，讨论毒理检测趋势和ADLM指导意见，没有新增订单、监管获批、产品商业化或业绩指引。
主要风险
- 若后续另有毒理检测产品获批、采购订单或医院渠道放量信息，需要作为新催化重新研判。
原文全文
展开原文 · 5,139 字
Beyond Fentanyl: How the Drug Crisis Is Changing
07/23/2026
Download this Press Release
PDF Format (opens in new window)
SAN DIEGO , July 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 59 of its Science Bytes podcast examining how the drug overdose landscape continues to evolve and what laboratory and emergency department professionals need to know to support patient care. Based on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM), the episode explores the growing complexity of toxicology testing amid counterfeit medications, polysubstance use and emerging synthetic opioids.
Hosted by Josh Casey, the episode features Vonda McAllister, Director of Global Product Management at QuidelOrtho. Together, they discuss encouraging declines in overdose mortality while highlighting the ongoing challenges facing clinicians and laboratorians as the illicit drug supply becomes increasingly unpredictable.
Key Insights:
U.S. overdose deaths declined for a third consecutive year in 2025, signaling progress in the fight against the opioid crisis
Counterfeit medications remain a significant threat, with millions of fentanyl-laced pills seized annually
Polysubstance use is increasingly common, creating more complex clinical presentations for patients
Emerging synthetic opioids such as nitazenes are attracting attention due to their potency and limited detectability in routine screening
New ADLM guidance emphasizes collaboration between laboratories and emergency departments to improve toxicology testing and interpretation
Despite progress in reducing overdose deaths, the discussion underscores that the crisis has not disappeared. Instead, it has evolved into a broader challenge requiring ongoing awareness, education and collaboration across the healthcare continuum.
The episode also highlights the critical role laboratories play in helping clinicians understand toxicology results, select appropriate testing strategies and make informed patient care decisions in rapidly changing drug environments.
Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
Stephanie Kleewein
Senior Corporate Communication and PR Manager
Media@QuidelOrtho.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/beyond-fentanyl-how-the-drug-crisis-is-changing-302832746.html
SOURCE QuidelOrtho Corporation
Categories:
Press Releases
View all news
Investor Alerts
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.
At QuidelOrtho Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.
By providing your email address below, you are providing consent to QuidelOrtho Corporation to send you the requested Investor Email Alert updates.
* Required
Email Address
*
Mailing Lists
*
News
Events
SEC Filings
Annual Reports
Financial Report
Email Alert Sign Up Confirmation
Investor Contact
Juliet Cunningham
QuidelOrtho
Vice President, Investor Relations
Juliet.cunningham@quidelortho.com
Erin Hart
QuidelOrtho
Senior Manager, Investor Relations
IR@QuidelOrtho.com
Jackie Marcus
Nick Teves
Alpha IR
-->
Vice President, Investor Relations
-->
858-646-8023
ruben.argueta@quidel.com
IR@QuidelOrtho.com -->
Transfer Agent
AMERICAN STOCK TRANSFER & TRUST COMPANY LLC.
(800) 937-5449 or (718)921-8124
help@astfinancial.com
https://www.astfinancial.com/
-->
Website:
www.computershare.com
Telephone inquiries:
1-800-736-3001, option 1 (U.S.)
1-781-575-3100, option 1 (non-U.S.)
E-mail inquiries:
web.queries@computershare.com
QuidelOrtho Corporation. All rights reserved. -->
Copyright © 2025 QuidelOrtho Corporation. All rights reserved.
Powered By Q4 Inc.
5.183.0.4
(opens in new window)
07/23/2026
Download this Press Release
PDF Format (opens in new window)
SAN DIEGO , July 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 59 of its Science Bytes podcast examining how the drug overdose landscape continues to evolve and what laboratory and emergency department professionals need to know to support patient care. Based on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM), the episode explores the growing complexity of toxicology testing amid counterfeit medications, polysubstance use and emerging synthetic opioids.
Hosted by Josh Casey, the episode features Vonda McAllister, Director of Global Product Management at QuidelOrtho. Together, they discuss encouraging declines in overdose mortality while highlighting the ongoing challenges facing clinicians and laboratorians as the illicit drug supply becomes increasingly unpredictable.
Key Insights:
U.S. overdose deaths declined for a third consecutive year in 2025, signaling progress in the fight against the opioid crisis
Counterfeit medications remain a significant threat, with millions of fentanyl-laced pills seized annually
Polysubstance use is increasingly common, creating more complex clinical presentations for patients
Emerging synthetic opioids such as nitazenes are attracting attention due to their potency and limited detectability in routine screening
New ADLM guidance emphasizes collaboration between laboratories and emergency departments to improve toxicology testing and interpretation
Despite progress in reducing overdose deaths, the discussion underscores that the crisis has not disappeared. Instead, it has evolved into a broader challenge requiring ongoing awareness, education and collaboration across the healthcare continuum.
The episode also highlights the critical role laboratories play in helping clinicians understand toxicology results, select appropriate testing strategies and make informed patient care decisions in rapidly changing drug environments.
Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
Stephanie Kleewein
Senior Corporate Communication and PR Manager
Media@QuidelOrtho.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/beyond-fentanyl-how-the-drug-crisis-is-changing-302832746.html
SOURCE QuidelOrtho Corporation
Categories:
Press Releases
View all news
Investor Alerts
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.
At QuidelOrtho Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.
By providing your email address below, you are providing consent to QuidelOrtho Corporation to send you the requested Investor Email Alert updates.
* Required
Email Address
*
Mailing Lists
*
News
Events
SEC Filings
Annual Reports
Financial Report
Email Alert Sign Up Confirmation
Investor Contact
Juliet Cunningham
QuidelOrtho
Vice President, Investor Relations
Juliet.cunningham@quidelortho.com
Erin Hart
QuidelOrtho
Senior Manager, Investor Relations
IR@QuidelOrtho.com
Jackie Marcus
Nick Teves
Alpha IR
-->
Vice President, Investor Relations
-->
858-646-8023
ruben.argueta@quidel.com
IR@QuidelOrtho.com -->
Transfer Agent
AMERICAN STOCK TRANSFER & TRUST COMPANY LLC.
(800) 937-5449 or (718)921-8124
help@astfinancial.com
https://www.astfinancial.com/
-->
Website:
www.computershare.com
Telephone inquiries:
1-800-736-3001, option 1 (U.S.)
1-781-575-3100, option 1 (non-U.S.)
E-mail inquiries:
web.queries@computershare.com
QuidelOrtho Corporation. All rights reserved. -->
Copyright © 2025 QuidelOrtho Corporation. All rights reserved.
Powered By Q4 Inc.
5.183.0.4
(opens in new window)
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。